2025 Oncology Institute
April 16, 2025 | 8:51 AM EST
Video Resources
NCODA educational videos help strengthen medically integrated healthcare providers with up-to-date and efficient information that can be applied to patient care. In the videos provided below, viewers will learn about appropriate dosing/dose modifications, adverse event management, treatment surveillance, adherence and persistence considerations, and clinical pearls.

Featured Videos

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide
Get quick, practical tips for safely administering the Akynzeo® Ready-to-Use vial—from tubing setup to pump programming—in this short video for infusion teams.
April 8, 2025 | 7:54 PM

Video: BRUKINSA® (Zanubrutinib) for Treatment of Mantle Cell Lymphoma
From safe handling and dispensing to patient education and adherence strategies, this resource equips pharmacy professionals with the tools they need to ensure safe, effective, and compassionate cancer care.
April 9, 2025 | 5:43 PM

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)
Joyce O’Shaughnessy, MD, Mina Guirguis, PharmD, and Amenda Lacy discuss Nerlynx (neratinib) for early-stage HER2-positive breast cancer, covering its benefits, side effect management, and patient experiences.
April 8, 2025 | 10:49 PM
Browse Educational Videos
Video
Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma
Supported By:
April 9, 2025

Video
Video: BRUKINSA® (Zanubrutinib) for Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Supported By:
April 9, 2025

Video

Video
Video: BRUKINSA® (Zanubrutinib) for Treatment of Waldenstrom’s Macroglobulinemia
Supported By:
April 8, 2025

Video
Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)
Supported By:
April 8, 2025

Video
Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer
Supported By:
April 8, 2025

Video
Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications
Supported By:
April 8, 2025

Video

Video
Tukysa® (tucatinib) Educational Videos
March 23, 2025
